


# the evolutionary dynamics of hematopoiesis (in health & disease)

Jorge M. Pacheco



<http://dl.dropbox.com/u/6053055/SP2016-1-of-5.pdf>



International Centre for Theoretical Physics  
South American Institute for Fundamental Research



## layout

mon – 12:00 – 13:15 : quantifying **HSC** in adult mammals

tues – 11:15 – 12:30 : ontogenic growth & **HSC** in humans

wed – 11:15 – 12:30 : from **HSC** to circulating blood :

*the standard model* of hematopoiesis (**SM**)

thu – 11:15 – 12:30 : disease in hematopoiesis

fri – 11:15 – 12:30 : extensions & challenges of the **SM**

# layout

monday – 12:00 – 13:15

- ❖ hematopoiesis : facts & fiction
- ❖ quantifying hematopoiesis : many questions, few answers
- ❖ hematopoietic stem cells (HSC)
- ❖ quantifying HSC in adult mammals : allometry & HSC scaling

**why quantifying hematopoiesis**


## landmarks in hematology

### oldest discipline in Medicine


- 1628** concept of circulation was 1<sup>st</sup> introduced
- 1662** 1<sup>st</sup> **IV** injection in humans
- 1667** 1<sup>st</sup> blood transfusion (lamb → human)
- 1770** W. Hewson identifies leucocytes (father of Hematology)
- 1818** 1<sup>st</sup> blood transfusion (human → human)
- 1901** blood groups are identified
- 1908** stem-cell concept was first conceived
- 1936** 1<sup>st</sup> blood bank in the USA
- 1962** 1<sup>st</sup> factor to treat coagulation disorders in hemophilic
- 1963** blood cell self-renewal is first identified in mice
- 1968** 1<sup>st</sup> bone-marrow transplantation
- 1971** war on cancer was declared
- 1972** stem-cell concept is first established in human blood
- 2010 ...** are we winning the war on cancer ?

# diversity in hematopoiesis


( formation & development of different types of blood cells )



neutrophils




lymphocytes



monocytes

( leucocytes )

bone marrow





red blood cell formation

one single origin:

**hematopoietic stem cells**


# the hematopoietic tree



Reya et al, *Nature*, 2001


# the hematopoietic tree

are the cell types depicted all types?  
if yes, how many cells of each type?



# the hematopoietic tree


are the cell types depicted all types?  
if yes, how many cells of each type?  
how long do cells of each type live?  
do they all function the same way?



Reya et al. *Nature*, 2001


# the hematopoietic tree

are the cell types depicted all types?  
if yes, how many cells of each type?  
how long do cells of each type live?  
do they all function the same way?  
do MPPs or CMPs or CLPs also self-renew?  
if yes, what fraction of time?



# the hematopoietic tree

are the cell types depicted all types ?  
if yes, how many cells of each type ?  
how long do cells of each type live ?  
do they all function the same way ?  
do MPPs or CMPs or CLPs also self-renew ?  
if yes, what fraction of time ?  
*is this important ?*  
*what about transplantation ?*




Reya et al. Nature, 2001

# the hematopoietic tree

*is this important ?*


*what about transplantation ?*

*2 recent articles in Nature try to investigate the difference between normal & stressed haematopoiesis*




Reya et al, Nature, 2001

**bone marrow  
“normal”**



**diversity**

**bone marrow  
“neoplastic”**



**uniformity  
(blasts)**

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?
- ❖ how do we know ? where do we look ? which cell type(s) ?

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?
- ❖ how do we know ? where do we look ? which cell type(s) ?
- ❖ does it happen in mice ? (experimentally: *no . . .*)

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?
- ❖ how do we know ? where do we look ? which cell type(s) ?
- ❖ does it happen in mice ? (experimentally: *no . . .*)
- ❖ is the mouse a good model for Humans ?

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?
- ❖ how do we know ? where do we look ? which cell type(s) ?
- ❖ does it happen in mice ? (experimentally: *no . . .*)
- ❖ is the mouse a good model for Humans ?
- ❖ if not, have we been wasting our time ?

# Cyclic Neutropenia (CN)

Dingli, Antal, Traulsen & Pacheco, Cell Proliferation 42 (2009) 330-338

Pacheco, Traulsen, Antal & Dingli, American Journal of Hematology, 83 (2008) 920

## *features*

- ❖ rare congenital disorder in hematopoiesis
- ❖  oscillations of neutrophil count
- ❖ it happens in humans ; it happens in dogs
- ❖ is it the same disease ? is the biology the same ?
- ❖ how do we know ? where do we look ? which cell type(s) ?
- ❖ does it happen in mice ? (experimentally: *no . . .*)
- ❖ is the mouse a good model for Humans ?
- ❖ if not, have we been wasting our time ?
- ❖ *and* money ? a mouse LAB costs 20 M€ to setup . . .

# Paroxysmal Nocturnal Hemoglobinuria (PNH)

## what is known :

- ❖ rare disease & a true stem-cell disorder since it originates in the PIG-A gene of a HSC
- ❖ rate of PIG-A gene mutation is normal
- ❖ often BMF is later observed

# Paroxysmal Nocturnal Hemoglobinuria (PNH)

## what is known :

- ❖ rare disease & a true stem-cell disorder since it originates in the PIG-A gene of a HSC
- ❖ rate of PIG-A gene mutation is normal
- ❖ often BMF is later observed

## present explanations regarding disease development :

- ❖ a 2<sup>nd</sup> mutation leads to a fitness advantage of PNH cells → disease expansion
- ❖ *relative fitness advantage* of PNH cells due to an **immune attack to normal HSC** → disease expansion

# Paroxysmal Nocturnal Hemoglobinuria (PNH)

## what is known :

- ❖ rare disease & a true stem-cell disorder since it originates in the PIG-A gene of a HSC
- ❖ rate of PIG-A gene mutation is normal
- ❖ often BMF is later observed

## present explanations regarding disease development :

- ❖ a 2<sup>nd</sup> mutation leads to a fitness advantage of PNH cells → disease expansion
- ❖ *relative fitness advantage* of PNH cells due to an **immune attack to normal HSC** → disease expansion

*does this make any sense at all ? how do we know ?  
where do we look ?*

# Chronic Myeloid Leukemia (CML)

## what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

# Chronic Myeloid Leukemia (CML)

what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

# Chronic Myeloid Leukemia (CML)

what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

*how does it progress from HSC to the peripheral blood ?*

# Chronic Myeloid Leukemia (CML)

## what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

*how does it progress from HSC to the peripheral blood ?*

*how & when to best treat it ?*

# Chronic Myeloid Leukemia (CML)

## what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

*how does it progress from HSC to the peripheral blood ?*

*how & when to best treat it ?*

*why are ABL-KINASE inhibitors effective ?*

# Chronic Myeloid Leukemia (CML)

## what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

*how does it progress from HSC to the peripheral blood ?*

*how & when to best treat it ?*

*why are ABL-KINASE inhibitors effective ?*

*how to fight resistance mutations ?*

# Chronic Myeloid Leukemia (CML)

## what is known :

- ❖ Hematopoietic stem cell disorder
- ❖ Initial event: Philadelphia chromosome
- ❖ ? HSC are enough to drive chronic phase ?
- ❖ clonal expansion and myeloproliferation
- ❖ stem cell derived but progenitor cell driven
- ❖ *abl*-kinase inhibitors very effective

*how long does it take to develop ?*

*how does it progress from HSC to the peripheral blood ?*



*how & when to best treat it ?*

*why are ABL-KINASE inhibitors effective ?*      *no idea...*

*how to fight resistance mutations ?*


building a math **model** of hematopoiesis

# the hematopoietic tree




Reya et al, *Nature*, 2001


# hematopoietic stem cells (HSC)



**self-renewal :**  
for how long ?  
( Hayflick hypothesis,  
telomere shortening )



**differentiation :**  
capacity to differentiate  
into all other types of blood cells



**stemness is a matter of degree – you have to stand at the  
root of the hematopoietic tree**

## characteristics of HSC

- ❖ *never been directly observed (their elusiveness reminds the *electron*)*
- ❖ *existence & abundance inferred mostly from experiments of reconstitution of bone marrow (via **transplant**) or by use of gene markers (no marker which uniquely identifies HSC . . . )*

## characteristics of HSC

- ❖ *never been directly observed (their elusiveness reminds the *electron*)*
- ❖ *existence & abundance inferred mostly from experiments of reconstitution of bone marrow (via **transplant**) or by use of gene markers (no marker which uniquely identifies HSC . . . )*

### **transplant :**

- ❖ *destruction of bone marrow (chemo-t..., radio-t...)*
- ❖ *infusion of marrow cells (including HSC)*  
*( from another mouse genetically identical )*
- ❖ *reconstitution of bone marrow (≈ 2 phase process)*
  - **fast** : induced by “progenitor” cells
  - **slow** : stabilization – HSC ( ≈1 year in humans . . . )

## properties of HSC

- ❖ *slow rate of replication ( ~ once / year )*
- ❖ *contribute to hematopoiesis for long periods of time ( perhaps the entire lifespan of the animal ? )*
- ❖ *statistical model of HSC data collected from different mammals led authors to propose that the total number of HSC is conserved in mammals.*
- ❖ *contribution to hematopoiesis occurs in “niches”, which set the “right” micro-environment*
- ❖ *stochastic behaviour ? if stochastic, how and with which consequences ?*

## problems of HSC

### ❖ *bone marrow failure*

*hereditary ( dyskeratosis congenita, Diamond-Blackfan anemia )*

*acquired ( paroxysmal nocturnal hemoglobinuria, **PNH** )*

### ❖ *Neoplasias*

*myeloid ( chronic myeloid leukemia, **CML** )*

*( therapy: tyrosine kinase inhibitors :*

*imatinib, dasatinib, nilotinib )*

*lymphoid*

## *HSC: many questions, few (scattered) answers*

- ❖ *how many HSC ?*
- ❖ *how long do they live ?*
- ❖ *how often do they replicate ?*
- ❖ *what's their dynamics of replication ?*
- ❖ *how to characterize the hematopoietic tree ?*
- ❖ *how to understand disease in this context ?*


# HSC scaling in mammals

Dingli & Pacheco, *PLoS ONE*, 2006

## cell metabolic rates

similarly to metabolic rate and many other energy related quantities in biology, also **hematopoiesis** should obey **allometric scaling relations**, reflecting common underlying organizational principles in, e.g., mammals:


**allometry** : scaling relations of type  $Y = Y_0 M^a$  (M=mass)



$$\text{Log}(Y) = \text{Log}(Y_0) + a \text{Log}(M)$$

# organism cell requirements

*different animals have different blood requirements !*




$$\text{Log}(Y) = \text{Log}(Y_0) + a \text{Log}(M)$$

*rate of blood production in the bone-marrow :*

*mouse (2 years)  $\approx$  cat (1 week)  $\approx$  man (1 day)*

# a scaling model of HSCs - 1

*we assume all mammals have the same hematopoietic tree structure . . .*




Dingli & Pacheco, *PLoS ONE*, 2006


*. . . data recently available supports this hypothesis*

## a scaling model of HSCs - 2

number of reticulocytes :  $N_R$   
 specific metabolic rate :  $\rho_c \sim M^{-1/4}$   
 retics maturation time :  $\tau \sim \rho_c^{-1}$



## a scaling model of HSCs - 3



$$N_{SC} \sim M^{3/4}$$

$$N_{SC} = N_0 M^{3/4}$$

## a scaling model of HSCs - 4

use experimental estimates for **cats** for calibration ( **fix  $N_0$**  ):  
 under normal conditions,  $\geq 40$  ! ( Abkowitz et al, Blood, 2002 )

what	model predictions ×	experimental data
<b>HSC in humans</b> cat = 40	<b>385</b>	<b>~400</b> ( Buescher et al, J Clin Invest, 1985 )
<b>rate HSC division</b> cat post-TRX = 8 week <sup>-1</sup>	<b>60 week<sup>-1</sup></b>	<b>~ 52-104 week<sup>-1</sup></b> ( Rufer, et al, J Exp Med, 1999 )
<b>human post-transplant</b> cat = 13	<b>111</b>	<b>~ 116</b> ( Nash et al, Blood, 1988 )
<b>mouse</b>	<b>1</b>	<b>1</b> ( Abkowitz et al, PNAS, 1995 )
<b>rate macaques</b>	<b>23 week<sup>-1</sup></b>	<b>23 week<sup>-1</sup></b> ( Shepherd et al, Blood, 2007 )
<b>rate baboons</b>	<b>36 week<sup>-1</sup></b>	<b>36 week<sup>-1</sup></b> ( Shepherd et al, Blood, 2007 )